



## Evonetix named Life Science Company of the Year at Cambridge Independent Science and Technology Awards

*Prestigious award granted in recognition of novel gene synthesis technology*

**CAMBRIDGE, UK 19 April 2021** – EVONETIX LTD ('Evonetix'), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, has been named "Life Science Company of the Year" at the 4<sup>th</sup> Cambridge Independent Science and Technology Awards. The Award recognises the potential of Evonetix's novel gene synthesis technology, as well as the Company's recent achievements. These include the close of a \$30M (£24M) Series B investment round, commercial partnerships with global industry leaders such as ADI and imec, and continued expansion. Evonetix aims to add staff across all areas of its technology including marketing and business development as it gears up for product launch.

Evonetix's novel platform has the potential to facilitate the rapidly growing field of synthetic biology. It will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used which will have a huge impact on enabling the growing multi-billion dollar synthetic biology industry. The technology is based on a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of up to 10,000 miniaturised reaction sites.

The Cambridge Independent Science and Technology Awards recognise outstanding life science and biotechnology companies in Cambridge. The ceremony took place virtually in a bespoke interactive environment, and was attended by leaders of businesses, organisations and research institutes across the Cambridge region on April 15, 2021.

**Tim Brears, CEO of Evonetix, said:** *"Our approach to synthesising long DNA at unprecedented accuracy and scale will have a great impact on the field of synthetic biology. This prestigious award recognises all that the team at Evonetix has achieved in the last year, despite the challenging conditions."*

**ENDS**

For a high-resolution image please contact Zyme Communications.



*Tim Brears,  
CEO, Evonetix*

**For further information, please contact:**

Lorna Cuddon  
Zyme Communications  
Tel: +44(0)7811996942  
Email: [lorna.cuddon@zymecommunications.com](mailto:lorna.cuddon@zymecommunications.com)

## **Notes to Editors**

### **About Evonetix Ltd**

Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA at unprecedented accuracy and scale. The company's platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used. This new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology.

The proprietary Evonetix approach utilises a silicon chip, made by MEMS processing, that integrates physics with biology, and controls the synthesis of DNA at many thousands of independently controlled reaction sites or 'pixels' on the chip surface in a highly parallel fashion. The approach is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, providing accuracy that is several orders of magnitude better than the conventional approach.

The Evonetix DNA writer will be a desktop device, available to every researcher, and providing scalable, accurate DNA synthesis to enable biological systems to be engineered with unprecedented accuracy and scale – this is third-generation DNA synthesis.

For further information, see [www.evonetix.com](http://www.evonetix.com)